Georg Stussi
Bellinzona, TI, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 95 publications
Real-world experience with posttransplant maintenance therapy in patients with myeloid neoplasms with active disease before allogeneic hematopoietic cell transplantation.
Journal: Bone marrow transplantation
Published: April 16, 2026
Flow Cytometry-Based Measurable Residual Disease Assessment in Patients With Acute Myeloid Leukemia Receiving Non-Intensive Chemotherapy.
Journal: American journal of hematology
Published: January 29, 2026
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.
Journal: bioRxiv : the preprint server for biology
Published: July 14, 2025
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.
Journal: Blood
Published: May 14, 2025
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.
Journal: Blood
Published: May 14, 2025
Polatuzumab vedotin and CD79B: A study of efficacy in R-CHOP-resistant diffuse large B-cell lymphoma.
Journal: British journal of haematology
Published: February 15, 2025
CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agents.
Journal: Leukemia
Published: November 09, 2024
Technical comment on: Trottmann M, et al. Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data.
Journal: Swiss medical weekly
Published: October 28, 2024
A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA.
Journal: Blood
Published: October 23, 2024
Ibrutinib lead-in followed by venetoclax plus ibrutinib for relapsed/refractory chronic lymphocytic leukemia: the SAKK 34/17 trial.
Journal: Blood
Published: September 16, 2024
Last Updated: 09/26/2026